Shriram Finance infuses ₹300 crore in Shriram Overseas

Shriram Finance Limited announced on Friday (September 26) that it has invested an additional ₹300.05 crore in its wholly-owned subsidiary, Shriram Overseas, as part of a phased capital infusion approved

by the board in May 2025.

The investment was made by subscribing to 1.90 crore equity shares at a face value of ₹10 each, with a premium of ₹147.69 per share.

Shriram Finance has undertaken a phased capital infusion in its wholly-owned subsidiary Shriram Overseas, with the board approving a total infusion of up to ₹500 crore in May 2025.

“The objective of the capital infusion in Shriram Overseas is to further strengthen its capital base,” the company said in a statement.

The shares were subscribed through a rights issue, representing 100% of the rights issue size.

Shriram Overseas reported a turnover of ₹3.26 crore for the financial year 2024-25. The company had posted ₹3.63 crore in FY24 and ₹2.14 crore in FY23.

Shriram Overseas primarily engages in investment activities, including acquiring, subscribing to, underwriting, and disposing of shares, bonds, securities, and debentures of companies in India and abroad.

Shriram Finance Q1 results

Shriram Finance reported a net profit of ₹2,159.4 crore for the June quarter, marginally below the CNBC-TV18 poll estimate of ₹2,164 crore, but marking a 6.3% year-on-year increase from ₹2,031 crore. Net interest income (NII) stood at ₹5,773 crore, up 10.3% from ₹5,234 crore a year ago, though slightly below the estimated ₹6,002 crore. Operating profit came in at ₹4,192 crore, below the Street expectation of ₹4,422 crore.

Shares of Shriram Finance Ltd ended lower on Friday (September 26) by 1.09% at ₹606 on the NSE.

Also Read: Lemon Tree Hotels names Patanjali Keswani as chairman, Neelendra Singh as MD in top brass recast